Article Information
PubMed
Print ISSN
Online ISSN
History
- Received April 5, 2022
- Accepted August 31, 2022
- Published online February 23, 2023.
Article Versions
- Earlier version (October 14, 2022 - 03:10).
- Earlier version (February 21, 2023 - 05:25).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2023 by The Author(s) This is an open access article distributed under the CC BY Attribution 4.0 International license.
Author Information
- Irmgard Hofmann,
- Anke Baum,
- Marco H. Hofmann,
- Francesca Trapani,
- Claudia Reichel-Voda,
- Diane Ehrensperger,
- Martin Aichinger,
- Florian Ebner,
- Nicole Budano,
- Norbert Schweifer,
- Martina Sykora1,
- Erik Depla2,
- Joachim Boucneau3,
- Andreas Gschwind,
- Norbert Kraut,
- Frank Hilberg, and
- Klaus-Peter Künkele4
- Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.)
- Address correspondence to:
Irmgard Hofmann, Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Dr.-Boehringer-Gasse 5-11, 1121 Vienna, Austria. E-mail: irmgard.hofmann{at}boehringer-ingelheim.com
Statistics from Altmetric.com
Article usage
In this issue
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement